Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.00546 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Matthias Stelljes und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Despite recent advances in adapting the intensity of treatment for older patients with ALL, current protocols are associated with high rates of early deaths, treatment-related toxicity, and dismal prognosis. We evaluated inotuzumab ozogamicin and dexamethasone (Dex) as induction therapy in older patients with ALL within the German Multicenter Study Group for Adult ALL (GMALL). PATIENTS AND METHODS The open-label, multicenter, phase II, INITIAL-1 trial enrolled 45 patients older than 55 years with newly diagnosed, CD22-positive, BCR::ABL-negative B-precursor ALL (B-ALL). Patients received up to three cycles of inotuzumab ozogamicin/Dex and up to six cycles of age-adapted GMALL consolidation and maintenance therapy. RESULTS Forty-three evaluable patients with common/pre-B (n = 38) and pro-B ALL (n = 5), with a median age of 64 years (range, 56-80), received at least two cycles of inotuzumab ozogamicin induction therapy. All patients achieved complete remission (CR/CR with incomplete hematologic recovery). Twenty-three (53%) and 30 (71%) patients had no evidence of molecularly assessed measurable residual disease (minimum 10e−4 threshold) after the second and third inductions, respectively. After a median follow-up of 2.7 years, event-free survival at one (primary end point) and 3 years was 88% (95% CI, 79 to 98) and 55% (95% CI, 40 to 71), while overall survival (OS) was 91% (95% CI, 82 to 99) and 73% (95% CI, 59 to 87), respectively. None of the patients died during 6 months after the start of induction. Most common adverse events having common toxicity criteria grade ≥3 during induction were leukocytopenia, neutropenia, thrombocytopenia, anemia, and elevated liver enzymes. One patient developed nonfatal veno-occlusive disease after induction II. CONCLUSION Inotuzumab ozogamicin–based induction followed by age-adapted chemotherapy was well tolerated and resulted in high rates of remission and OS. These data provide a rationale for integrating inotuzumab ozogamicin into first-line regimens for older patients with B-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany.
- Department of Medicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
- Medizinische Klinik und Poliklinik I, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
- Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
ORCID-Profile: Matthias Stelljes, Ralph Wäsch, Mustafa Kondakci, Sonja Martin, Hubert Serve, Wolfgang E Berdel, Klaus Wethmar
Zitieren
APA
Stelljes, M., Raffel, S., Alakel, N., Wäsch, R., Kondakci, M., Scholl, S., Rank, A., Hänel, M., Spriewald, B., Hanoun, M., Martin, S., Schwab, K., Serve, H., Reiser, L., Knaden, J., Pfeifer, H., Marx, J., Sauer, T., Berdel, W. E., …, & Wethmar, K. (2024). Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00546
Vancouver
Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, et al. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.00546
BibTeX
@article{Stelljes2024,
author = {Stelljes, Matthias and Raffel, Simon and Alakel, Nael and Wäsch, Ralph and Kondakci, Mustafa and Scholl, Sebastian and Rank, Andreas and Hänel, Mathias and Spriewald, Bernd and Hanoun, Maher and Martin, Sonja and Schwab, Katjana and Serve, Hubert and Reiser, Lena and Knaden, Julian and Pfeifer, Heike and Marx, Julia and Sauer, Tim and Berdel, Wolfgang E and Lenz, Georg and Brüggemann, Monika and Gökbuget, Nicola and Wethmar, Klaus},
title = {Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.00546}
}
EUVIMED